Información del artículo
El Texto completo está disponible en PDF
Biblografía
[1.]
J.O.L. Jorgensen, L. Thuesen, T. Ingemannhansen, S.A. Pedersen, J. Jorguensen, N.E. Skakkebaek, et al.
Beneficial effects of growth hormone treatment in GHD-deficient adults.
Lancet, 1 (1989), pp. 1221-1225
[2.]
F. Salomon, R.C. Cuneo, R. Hesp, P.H. Sonksen.
The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency.
N Engl J Med, 321 (1989), pp. 1797-1803
[3.]
R.C. Cuneo, F. Salomon, G.A. McGauley, P.H. Sönksen.
The growth hormone deficiency syndrome in adults.
Clin Endocrinol, 37 (1992), pp. 387-397
[4.]
H. De Boer, G.J. Blok, A. Van der Veen.
Clinical aspects of growth hormone deficiency in adults.
Endoc Rev, 16 (1995), pp. 63-86
[5.]
M.E. Wallymahmed, P. Foy, I.A. MacFarlane.
The quality of life of adults with growth hormone deficiency: comparison with diabetic patients and control subjects.
Clin Endocrinol, 51 (1999), pp. 333-338
[6.]
A.F. Attanasio, S.W. Lamberts, A.M. Matranga, M.A. Birkett, P.C. Bates, N.K. Valk, et al.
Adult growth hormone (GH)– deficient patients demonstrate heterogeneity between childhood onset and adult onset before and during human GH treatment. Adult Growth Hormone Deficiency Study Group.
J Clin Endocrinol Metab, 82 (1997), pp. 82-88
[7.]
R. Abs, B.A. Bengtsson, E. Hernberg-Stahl, J.P. Monson, J.P. Tauber, P. Wilton, et al.
GH replacement in 1034 growth hormone deficient hypopituitary adults: demographic and clinical characteristics, dosing and safety.
Clin Endocrinol, 50 (1999), pp. 703-713
[8.]
W.M. Drake, J. Rodríguez-Arnao, J.U. Weaver, T. Spector, I.T. James, G.M. Besser, et al.
The effect of long term GH replacement on bone mineral density and metabolism in hypopituitary adults.
Clin Endocrinol, 54 (2001), pp. 525-532
[9.]
X. Badía, A. Lucas, A. Sanmartí, M. Roset, A. Ulied.
on behalf of the Collaborative ODA Group. One year follow-up of quality of life in adults with untreated growth hormone deficiency.
Clin Endocrinol, 49 (1998), pp. 765-771
[10.]
A. Sanmartí, A. Lucas, F. Hawkins, S.M. Webb, A. Ulied.
on behalf of the Collaborative ODA (Observational GH Deficiency in Adults) Group. Observational study in adult hypopituitary patients with untreated growth hormone deficiency (ODA study). Socio-economic impact and health status.
Eur J Endocrinol, 141 (1999), pp. 481-489
[11.]
J.O. Johansson, K. Landin, L. Tengborn, T. Rosén, B.A. Bengtsson.
High fibrinogen and plasminogen activator inhibitor activity in growth hormone–deficient adults.
Arterioscler Thromb, 14 (1994), pp. 434-437
[12.]
G. Sesmilo, B.M.K. Biller, J. Llevadot, D. Hayden, G. Hanson, N. Rifai, et al.
Effects of growth hormone (GH) administration on homocyst(e)ine levels in men with GH deficiency: a randomized controlled trial.
J Clin Endocrinol Metab, 86 (2001), pp. 1518-1524
[13.]
V. Markussis, S.A. Beshyah, C. Fisher, P. Sharp, A.N. Nicolaides, D.G. Johnston.
Abnormal carotid arterial wall dynamics in symptom-free hypopituitary adults.
Eur J Endocrinol, 136 (1997), pp. 157-164
[14.]
T. Rosén, B.A. Bengtsson.
Premature mortality due to cardiovascular disease in hypopituitarism. Epidemiology.
Lancet, 336 (1990), pp. 285-288
[15.]
A.S. Bates, W. Wan't Hoff, P.J. Jones, R.N. Clayton.
The effect of hypopituitarism on life expentancy.
J Clin Endorinol Metab, 81 (1996), pp. 1169-1172
[16.]
A.S. Bates, B. Bullivant, M.C. Sheppard, P.M. Stewart.
Life expentancy following surgery for pituitary tumours.
Clin Endocrinol, 50 (1999), pp. 315-319
[17.]
B. Bülow, L. Hagmar, Z. Mikoczy, C.H. Nordström, E.M. Erfurth.
Increased cerebrovascular mortality in patients with hypopituitarism.
Clin Endrocrinol, 46 (1997), pp. 75-81
[18.]
E.M. Erfurth, B. Bülow, L.E. Hagmar.
Is vascular mortality increased in hypopituitarism?.
Pituitary, 3 (2000), pp. 77-81
[19.]
B. Bülow, L. Hagmar, J. Eskilsson, E.M. Erfurth.
Hypopituitary females have a high incidence of cardiovascular morbidity and an increase Prevalence of Cardiovascular risk factors.
J Clin Endocrinol Metab, 85 (2000), pp. 574-584
[20.]
B. Nilsson, E. Gustavsson-Kadaka, B.A. Bengtsson, B. Jonsson.
Pituitary adenomas in Sweeden between 1958 and 1991: incidence, survival and mortality.
J Clin Endocrinol Metab, 85 (2000), pp. 1420-1425
[21.]
T.A.M. Abdu, R. Neary, T.A. Elhadd, M. Akber, R.N. Clayton.
Coronary risk in growth hormone deficient hypopituitary adults: increased predicted risk is due largely to lipid profile abnormalities.
Clin Endocrinol, 55 (2001), pp. 209-216
[22.]
J.W. Tomlinson, N. Holden, R.K. Hills, K. Wheatley, R.N. Clayton, A.S. Bates, et al.
and the West Midlands Prospective Hipopituitary Study Group. Association between premature mortality and hypopituitarism.
Lancet, 357 (2001), pp. 425-431
[23.]
A.J. Swerdlow.
Design and interpretation of studies of the risk of cancer and other long-term morbidity and mortality after growth hormone treatment.
Growth Horm IGF Res, (2000), pp. 318-323
Copyright © 2002. Sociedad Española de Endocrinología y Nutrición